Drug Approval | August 28, 2021
DCGI approves Enzene biosimilar Denosumab for Osteoporosis
This is Enzene Biosciences third biosimilar to be approved
This is Enzene Biosciences third biosimilar to be approved
It is the only biopharmaceutical company in India to offer all three dosage strengths of the drug (125mcg, 250mcg, and 500mcg)
Sadhana Nitro Chem's plant is the second plant in the world to manufacture pAP from Nitrobenzene
The company completed paracetamol capacity expansion by 1,800 MTPA and the company is now focusing on frugal manufacturing practices to reduce raw material cost and expand margins
The company registered with REACH Certificate for Ethyl Acetate with a tonnage band of more than 1000 TPA
Q2 FY23 business performance has been slow primarily due to lower volume offtake from pharmaceutical manufacturers
The company is now introducing the product into the India pharmaceutical market.
An amount of Rs. 70.9 crore has been earmarked for funding capital expenditure for the proposed expansion
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)